KalVista Pharmaceuticals, based in Cambridge, Massachusetts, specializes in small molecule protease inhibitors for unmet medical needs, focusing on hereditary angioedema treatments like sebetralstat and Factor XIIa inhibitors. The company went public in April 2015 and employs 150 staff.
Paul K Audhya sold 8,077 shares of KALV on 18 November at $9.26 per share, worth a total of $75K. They now own 94,199 KALV shares, or a 8% holding decrease.
📡️ Health Care
Insider Trades
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
